N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

A compound of structural Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is selected from monocyclic or bicyclic C3-8 carbocycle, said carbocycle optionally interrupted by an oxygen atom and optionally substituted with 1 to 3 groups selected from C1-6 alkyl, (CH2)nOC1-6alkyl, CN, C1-3haloalkyl, C3-10 heteroaryl, C3-10 heterocyclyl, and halogen, said heteroaryl and heterocyclyl optionally substituted with 1 to 3 groups selected from C1-6 alkyl, CF3, and CN;
• R2 is selected from hydrogen, C1-6 alkyl, OC1-6alky, C3-6 cycloalkyl, and halogen;
• R3 is selected from N-linked oxo-oxazolidinyl, oxoazabicycloheptanyl, azabicycloheptanyl, piperidinyl, tetrahydropyrazolopyridinyl, azaspiroheptanyl, and piperazinyl said N-linked oxazolidinyl, oxazolidinonyl, oxoazabicycloheptanyl, piperidinyl, tetrahydropyrazolopyridinyl, azaspiroheptanyl, and piperazinyl unsubstituted or substituted with 1 to 3 groups independently selected from C1-6 alkyl, OC1-6 alkyl, OH, halogen, CN, azetidinyl, wherein said piperazinyl is further substituted at available nitrogen atom with a group independently selected from C1-6 alkyl, oxetanyl, azetidinyl, and tetrahydrofuranyl, said oxetanyl, azetidinyl, and tetrahydrofuranyl unsubstituted or substituted with 1 to 2 groups independently selected from C1-6 alkyl, OC1-6 alkyl, halogen, CN, and OH and n is selected from 0 to 3.